Diabetes is on the rise in children and young people

Published Date: 10 Mar 2023

New findings from researchers at Wake Forest University School of Medicine show that the rate of type 1 and type 2 diabetes is increasing...

Read Full News

Latest News

TRANSCEND-T2D-2: Retatrutide Beats Semaglutide 2 mg on A1C, Weight Loss

TRANSCEND-T2D-2: Retatrutide Beats Semaglutide 2 mg on A1C, Weight Loss

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

4 Endocrinology Headlines You Missed in August 2026 Chelsie Derman

New approval for tirzepatide, phase 3 wins for avexitide and retatrutide, and a GLP-1 telehealth safety gap in August's biggest endocrinology stories.

Icodec-Semaglutide Combo Outperforms Glargine in T2D Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent clinical success of IcoSema, an investigational insulin-semaglutide combination treatment.

Revita Reduces Weight Regain After GLP-1 Discontinuation in REMAIN-1

Revita Reduces Weight Regain After GLP-1 Discontinuation in REMAIN-1

Todays Updates

AD109 Cuts AHI by 59.6% in Postmenopausal Women With OSA Reena Mehra, MD

In a post hoc analysis of 2 phase 3 trials, AD109 reduced hypoxic burden by 69.8% vs 20.0% with placebo in postmenopausal women with OSA.

Mucus Plug Reduction with Type 2 Biologics: Lessons for COPD

Mucus Plug Reduction with Type 2 Biologics: Lessons for COPD

2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics

2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics

Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD

Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD

Distinguishing Lambert-Eaton Myasthenic Syndrome From Ocular Myasthenia Gravis in the Eye Clinic Marco Meglio

Kiril Kiprovski, MD, clinical professor of neurology and director of the Division of Neuromuscular Medicine at NYU Langone, reviews the clinical clues, bedside tests, and referral considerations that help eye care clinicians identify Lambert-Eaton myasthenic syndrome in patients with fluctuating ptosis or diplopia.

PREVAiLS Phase 3 Trial Evaluates Pridopidine in Early, Rapidly Progressive ALS Louie Pasculli

The 500-participant study will assess whether pridopidine, an investigational sigma-1 receptor agonist, can slow functional decline and improve survival in patients with early, rapidly progressing amyotrophic lateral sclerosis.

Todays Updates

AD109 Cuts AHI by 59.6% in Postmenopausal Women With OSA Reena Mehra, MD

In a post hoc analysis of 2 phase 3 trials, AD109 reduced hypoxic burden by 69.8% vs 20.0% with placebo in postmenopausal women with OSA.

Mucus Plug Reduction with Type 2 Biologics: Lessons for COPD

Mucus Plug Reduction with Type 2 Biologics: Lessons for COPD

2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics

2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics

Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD

Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD

Distinguishing Lambert-Eaton Myasthenic Syndrome From Ocular Myasthenia Gravis in the Eye Clinic Marco Meglio

Kiril Kiprovski, MD, clinical professor of neurology and director of the Division of Neuromuscular Medicine at NYU Langone, reviews the clinical clues, bedside tests, and referral considerations that help eye care clinicians identify Lambert-Eaton myasthenic syndrome in patients with fluctuating ptosis or diplopia.

PREVAiLS Phase 3 Trial Evaluates Pridopidine in Early, Rapidly Progressive ALS Louie Pasculli

The 500-participant study will assess whether pridopidine, an investigational sigma-1 receptor agonist, can slow functional decline and improve survival in patients with early, rapidly progressing amyotrophic lateral sclerosis.

Latest News

TRANSCEND-T2D-2: Retatrutide Beats Semaglutide 2 mg on A1C, Weight Loss

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

New approval for tirzepatide, phase 3 wins for avexitide and retatrutide, and a GLP-1 telehealth safety gap in August's biggest endocrinology stories.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent clinical success of IcoSema, an investigational insulin-semaglutide combination treatment.

Revita Reduces Weight Regain After GLP-1 Discontinuation in REMAIN-1

News All Time

Retatrutide Improves Weight Loss, Knee Osteoarthritis Pain, Sleep Apnea Versus Placebo

Retatrutide Improves Weight Loss, Knee Osteoarthritis Pain, Sleep Apnea Versus Placebo

Semaglutide 2 mg Escalation Tied to Lower MACE vs Tirzepatide Switch in T2D

Semaglutide 2 mg Escalation Tied to Lower MACE vs Tirzepatide Switch in T2D

REMAIN-1: Improved GLP-1-Induced Weight Loss Retention With Revita DMR System Ryan Livingston

New data from the 45-patient Midpoint Cohort, despite not being powered for statistical significance, indicate a potentially substantial benefit.

FIND-CKD Trial Poses Finerenone as a "Third Pillar" for Nondiabetic CKD Rajiv Agarwal, MD, MS

Phase 3 FIND-CKD data show finerenone slows kidney decline and reduces CV events in adults with nondiabetic CKD, Rajiv Agarwal, MD, adds his perspective.

FDA Accepts Resubmitted CAM2029 NDA for Acromegaly Ryan Livingston

FDA accepted Camurus’ resubmitted CAM2029 application for acromegaly, with a target action date of December 18, 2026.

Survey Shows Peptide Misinformation, Misuse Rising in US Ashish Rana, MD

Ashish Rana, MD, discusses Sermo’s recent clinician survey, which highlighted patients’ use of unapproved and compounded GLP-1 medications.

FDA Accepts NDA for Encaleret for Autosomal Dominant Hypocalcemia Type 1 Ryan Livingston

If approved, encaleret will be the first treatment specifically indicated for this underrepresented patient population.

Continuous Glucose Monitoring in Type 2 Diabetes, With John Anderson, MD John Anderson, MD

Anderson discusses recent advancements in CGM technology, as well as the myriad behavioral and clinical benefits of CGM use in T2D with or without insulin.

5 Endocrinology Headlines You Missed in July 2026 Ryan Livingston

New Drug Applications and key trial readouts punctuated July for endocrinology, with treatments for hypocalcemia, diabetes, and more.

Retatrutide Meets Phase 3 Weight-Loss Endpoints in 2 Obesity Trials Ryan Livingston

Retatrutide met 80-week weight-loss endpoints in TRIUMPH-2 and TRIUMPH-3, prompting a planned FDA submission in Q1 2027.

Medically Tailored Groceries Improve Blood Sugar Control, Nutrition in T2D Ryan Livingston

A recent study from Kaiser Permanente has indicated substantial HbA1c improvements among patients receiving food-based support.

TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With Obesity Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, discuss the topline results of the TRIUMPH-2 trial of retatrutide.

Ascendis Reports 78-Week Data From COACH Trial for Achondroplasia Ryan Livingston

Combination therapy with navepegritide and lonapegsomatropin has demonstrated its efficacy in improving mean annualized growth velocity in pediatric patients.

Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3 Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss topline data from the TRIUMPH-3 trial of retatrutide.

500,000 Patients With Diabetes May Lose Healthcare Under New Medicaid Legislation Ryan Livingston

Limits to provider taxes used to fund Medicaid programs, as well as increased eligibility requirements and cost-sharing obligations, may make insurance inaccessible.

Secret Shopper Study Reveals GLP-1 Telehealth Gaps Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the risks of ordering GLP-1 RAs online.

Recommended News For You

A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma

Lymph node transfer reduces arm swelling after breast cancer surgery, study shows

Breast density changes over time are associated with an increased risk of cancer.

3D Mammography Improves Long-Term Cancer Risk Prediction

Psychiatric Disorders Are Common in Dementia Patients.

HER2 ADC Shows Promise in Recurrent Endometrial Cancer

Delaying Pegfilgrastim May Curb Bone Pain in Breast Cancer

Recommended Articles For You

HKDC1 Protein: An Emerging Therapeutic Target in Colon Cancer 

Red Cell Adaptation During Female Reproductive Transitions: Mechanisms, Clinical Implications, and Evidence-Based Insights 

Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec 

Emerging Trends in Oncology and Precision Medicine 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

'Dawson's Creek' Star Has Cancer; Radiotherapy Tattoos; Case of 'Petticoat' Cancer

2.

A three-quarters reduction in the risk of prostate cancer is associated with an annual increase in cardiorespiratory fitness of more than three percent.

3.

EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.

4.

A Sinister Etiology for Shoulder Pain

5.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

1.

Clinical Pharmacology of Megakaryocyte Maturation-Targeted Therapeutics

2.

Therapeutic Innovations Through Germline Predisposition in Acute Leukemias and Myeloid Neoplasms

3.

Cancer Staging Education Through Interactive Anatomical Spread Maps

4.

Modern Developments in Oncology for Specialists

5.

Breaking Barriers: Innovative Approaches in Brain Tumor Treatment

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

A New Era in Managing Cancer-Associated Thrombosis

2.

Understanding the Common Causes of Anemia

3.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII

4.

Learning About Different Treatment Approaches For Acute Lymphoblastic Leukemia

5.

Should We Use DARA Up Front As First-Line Therapy in MM?


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot